Therefore, antisense oligodeoxynucleotide targeted at BCL-2 (G3139) may serve as an appropriate therapeutic alternative for patients with BCL-2-positive synovial sarcomas [25]. This evidence concerns the gene BCL2 and synovial sarcoma.